Porcine circovirus, porcine pseudorabies virus and mycoplasma triple inactivated vaccine
A porcine pseudorabies virus, porcine circovirus technology, applied in the direction of virus antigen components, virus/phage, vaccines, etc., can solve the problems of high immunization frequency, easy recurrence, pig stress, etc., to simplify the immunization program, reduce The probability of side effects of vaccines and the effect of reducing the cost of epidemic prevention
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0029] The invention provides a technical scheme: porcine circovirus, porcine pseudorabies virus and mycoplasma triple inactivated vaccine, including antigen and vaccine adjuvant, and the antigen is composed of porcine circovirus type 2 antigen, porcine pseudorabies virus antigen and mycoplasma Antigen composition, the porcine circovirus type 2 antigen is purified, concentrated and inactivated porcine circovirus type 2 protein antigen solution, and the Cap protein content is ≥ 160 μg / ml; the porcine pseudorabies virus antigen is purified, concentrated and inactivated The porcine pseudorabies virus protein antigen solution, the Cap protein content is ≥ 160 μg / ml; the mycoplasma antigen is an inactivated mycoplasma protein antigen solution, and the Cap protein content is ≥ 160 μg / ml; the vaccine adjuvant is composed of a water-based polymer agent and compound polysaccharide immune enhancer.
[0030] In this embodiment, preferably, the water-based polymer adjuvant is Montanide Ge...
Embodiment 2
[0047] The invention provides a technical scheme: porcine circovirus, porcine pseudorabies virus and mycoplasma triple inactivated vaccine, including antigen and vaccine adjuvant, and the antigen is composed of porcine circovirus type 2 antigen, porcine pseudorabies virus antigen and mycoplasma Antigen composition, the porcine circovirus type 2 antigen is purified, concentrated and inactivated porcine circovirus type 2 protein antigen solution, and the Cap protein content is ≥ 160 μg / ml; the porcine pseudorabies virus antigen is purified, concentrated and inactivated The porcine pseudorabies virus protein antigen solution, the Cap protein content is ≥ 160 μg / ml; the mycoplasma antigen is an inactivated mycoplasma protein antigen solution, and the Cap protein content is ≥ 160 μg / ml; the vaccine adjuvant is composed of a water-based polymer agent and compound polysaccharide immune enhancer.
[0048] In this embodiment, preferably, the water-based polymer adjuvant is Montanide Ge...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com